A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.

@article{Olivieri2007ANI,
  title={A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.},
  author={Attilio Olivieri and Debora Capelli and Emanuela Troiani and Antonella Poloni and Mauro Montanari and Massimo Offidani and Giancarlo Discepoli and Pietro Leoni},
  journal={Experimental hematology},
  year={2007},
  volume={35 7},
  pages={
          1074-82
        }
}
OBJECTIVE We evaluated the feasibility of a new regimen in elderly patients with acute myeloid leukemia (AML). The main end points were overall response rate (ORR) and toxicity; secondary end points were feasibility of peripheral blood stem cells (PBSC) collection, leukemia-free survival, and overall survival (OS). PATIENTS AND METHODS We treated 42 fit elderly patients with high-dose (HD) idarubicin plus HD-cytarabine (Ara-C), with amifostine. RESULTS We observed one treatment-related… CONTINUE READING